The identification of tumor-reactive T cells using phenotypic markers is now well established in treatment-naive tumors. It is unclear, however, whether these markers can also be useful after immune checkpoint blockade (ICB). A new study finds that CXCL13 expression robustly identifies tumor-reactive T cells before and after ICB and is associated with treatment response.
This is a preview of subscription content, log in via an institution to check access.
References
Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Nat. Cancer https://doi.org/10.1038/s43018-022-00433-7 (2022).
Gros, A. et al. Nat. Med. 22, 433–438 (2016).
Scheper, W. et al. Nat. Med. 25, 89–94 (2019).
Tran, K. Q. et al. J. Immunother. 31, 742–751 (2008).
Simoni, Y. et al. Nature 557, 575–579 (2018).
Duhen, T. et al. Nat. Commun. 9, 2724 (2018).
Thommen, D. S. et al. Nat. Med. 24, 994–1004 (2018).
Oliveira, G. et al. Nature 596, 119–125 (2021).
Lowery, F. J. et al. Science 375, 877–884 (2022).
Caushi, J. X. et al. Nature 596, 126–132 (2021).
Litchfield, K. et al. Cell 184, 596–614.e14 (2021).
Zhang, Y. et al. Cancer Cell 39, 1578–1593.e8 (2021).
van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. Nat. Rev. Cancer 20, 218–232 (2020).
Garcia-Diaz, A. et al. Cell Rep. 19, 1189–1201 (2017).
David, J. M. et al. Oncoimmunology 6, e1349589 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kaptein, P., Thommen, D.S. Keeping track of the T cells that matter. Nat Cancer 3, 1015–1017 (2022). https://doi.org/10.1038/s43018-022-00432-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00432-8
- Springer Nature America, Inc.